Posted by Michael Wonder on 19 May 2025
Zai Lab receives US FDA fast track designation for ZL-1310, a DLL3 targeted antibody drug conjugate, for treatment of extensive stage small cell lung cancer
19 May 2025 - The Company is on track to initiate a pivotal study for ZL-1310 in small cell lung cancer in 2025.
Zai Lab today announced the US FDA has granted fast track designation to ZL-1310, the Company’s potential first in class delta like ligand antibody-drug conjugate, for the treatment of extensive-stage small cell lung cancer.
